Background Excimer laser therapy of vitiligo generally takes months to years to achieve excellent outcomes. Platelet‐rich plasma is an autologous preparation with a focus on various growth factors that can help with vitiligo repigmentation. Objectives To assess the additive effect of PRP in the therapy of vitiligo on the results of the excimer laser. Patients and Methods A comparative study included 52 patients (8 males and 44 females) in two groups with stable (no new lesion for 6 months), nonsegmental and symmetrical vitiligo. Group I (26 patients): The patient was treated by intradermal PRP injection and the excimer laser, while group II (26 patients) was treated with the excimer laser only. The PRP injection was repeated every 3 weeks for 4 months and excimer laser two times a week and for 16 weeks till complete response. VAS for patient's satisfaction assessment, safety assessment for complications, and follow‐up for 3 months was done. Clinical (repigmentation response) and histopathological assessment was done. Results There was a higher statistically significant treatment response in group I compared with group II. In addition, a statistically significant correlation between the treatment response and the lesion site in group I (P < .000). A significant difference in VAS between both groups (P < .000). Few the side effects were reported. Conclusion The combination of PRP and excimer laser phototherapy is an efficient vitiligo treatment as PRP increases the excimer laser impact and also improves the result.

• Hepatic observation may be categorized differently depending on the imaging modality used. • We compared LI-RADS categorization between CT, MRI and combined CT/MRI. • MRI produces higher accuracy and sensitivity, while CT produces higher specificity. • Combining CT and MRI improves LIRADS categorization reports. • Considering additional cost, combined methodology could be restricted to challenging cases.

We examined the effect of placenta-derived MSCs (PDMSCs) injection intraregionally and intraperitoneally on healing of induced full thickness mice skin wounds; moreover, the mechanisms by which MSCs exert their effects were also studied. Sixty female mice were divided into three groups after induction of full thickness skin wound; untreated group, wounded mice were injected with MSCs derived from human placenta intraperitoneally or intraregionally. Skin biopsies were obtained 7 and 12 days after wound incision for histological examinations, detection of vascular endothelial growth factor (VEGF) by ELISA, and estimation of expression of mouse ICAM-1, Integrin b1, Integrin b3 genes and human albumin and GAPDH genes by reverse transcription polymerase chain reaction. Human placenta derived-MSCs treated groups showed accelerated wound healing than non-treated group. VEGF, Integrin b1, and Integrin b3 levels were significantly increased in the intraregionally and intraperitoneally treated mice as compared to non-treated group at day 7 after wound induction. ICAM-1 showed significant decrease in its expression in treated groups compared with non-treated group. Interestingly, the intraperitoneal MSCs injections showed better results than intraregional one. PDMSCs accelerate full thickness skin wound healing and the intraperitoneal MSCs injections are more effective than intraregional one. MSCs promote wound healing through release of proangiogenic factors as VEGF, increase healing promoting factors as integrin b1 and b3, and decrease proinflammatory cytokines as ICAM-1. V C 2015 IUBMB Life, 67(9): [701][702][703][704][705][706][707][708][709] 2015

No abstract

No abstract